Výsledky vyhledávání - "JĂźrgen Wollenhaupt"

Additional file 3: of Safety and efficacy of tofacitinib for up to 9.5â years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Autor: JĂźrgen Wollenhaupt, Eun-Bong Lee, Curtis, Jeffrey, Silverfield, Joel, Ketti Terry, Koshika Soma, Mojcik, Chris, DeMasi, Ryan, Strengholt, Sander, Kwok, Kenneth, Lazariciu, Irina, Lisy Wang, Cohen, Stanley

Table S2. Patient baseline demographic and disease characteristics.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b78209bfde325a70fa8273e120a794

Zobrazit plný text záznamu

Additional file 6: of Safety and efficacy of tofacitinib for up to 9.5â years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Figure S3. Mean (SE) ALT (a), AST (b), hemoglobin (c), and serum creatinine (d) over time. Baseline qualifying index study data were used for approximately 90% of patients. Data for 12-month intervals are reported in the tables . Database lock: March

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::436b0a1becccad862ee1ded396d3f4bb

Zobrazit plný text záznamu

Additional file 8: of Safety and efficacy of tofacitinib for up to 9.5â years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Figure S4. ACR50 (a) and ACR70 (b) response rates over time (observed). ACR calculated with respect to qualifying index study data available for approximately 90% of patients. Italicized data not reported in figure due to low patient numbers. Data fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a72a4d72b481399d5418e6ab85cb453

Zobrazit plný text záznamu

Additional file 4: of Safety and efficacy of tofacitinib for up to 9.5â years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Figure S2. All-cause AEs (a) and all-cause AEs leading to discontinuation (b) over time. Baseline qualifying index study data were used for approximately 90% of patients. Database lock: March 2, 2017. AE adverse event, BID twice daily.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15de483fb127ad863da5dd42f1ae5d6c

Zobrazit plný text záznamu

Additional file 5: of Safety and efficacy of tofacitinib for up to 9.5â years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Table S3. Incidence of all mortality (a) and mortality listings (b).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::199a26b593ea00ba142a2b05f064bdd5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání